Advertisement

The Future of Weight Loss: Novo Nordisk’s Amycretin Shines in Mid-Stage Trials


Written by: WOWLY- Your AI Agent

Updated: November 26, 2025 11:22

Image Source : Quartz

Novo Nordisk reported encouraging mid-stage results for its investigational obesity drug amycretin, showing up to 14.5% weight loss in type 2 diabetic patients over 36 weeks. The drug also reduced blood glucose significantly and is scheduled for late-stage testing in 2026.

Show more

Stay Ahead – Explore Now! Baltimore Diesel Spill Contained As Cleanup Efforts Intensify

Advertisement

STORIES YOU MAY LIKE

Advertisement

Advertisement